Want to see JP:7730 full AI Analyst Report?
7730 Stock Chart & Stats
¥1500.50
¥30.00(1.62%)
At close: 4:00 PM EST
¥1500.50
¥30.00(1.62%)
Day’s Range― - ―
52-Week Range¥1,345.00 - ¥1,955.00
Previous CloseN/A
Volume546.10K
Average Volume (3M)293.86K
Market Cap
¥151.13B
Enterprise Value¥128.50B
Total Cash (Recent Filing)¥23.77B
Total Debt (Recent Filing)¥56.00M
Price to Earnings (P/E)20.9
Beta1.12
Next Earnings
Jan 13, 2027EPS Estimate
18.17Next Dividend Ex-DateN/A
Dividend Yield2.71%
Share Statistics
EPS (TTM)68.58
Shares Outstanding107,003,280
10 Day Avg. Volume407,090
30 Day Avg. Volume293,860
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.63
Price to Sales (P/S)4.69
P/FCF Ratio14.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)78.77
Revenue Forecast (FY)¥35.94B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthRevenue has grown steadily across several years and re-accelerated in the latest annual period. That trajectory indicates expanding demand for Mani’s dental and surgical products, supporting continued scale benefits and providing a durable base for investment, market development, and earnings growth over the next several quarters.
Improving ProfitabilityWider gross margins and a materially higher net margin show stronger profitability and improved cost control or product mix. If sustained, this creates more internal funding for research, capacity, and commercial investment while increasing the earnings contribution from future revenue growth.
Conservative Balance SheetExtremely low leverage materially reduces financial risk and leaves Mani with flexibility to support expansion without relying heavily on borrowing. Consistent growth in equity and assets also indicates that the company has been building its operating base while preserving balance-sheet resilience.
Bears Say
Volatile Free Cash FlowFree cash flow has not tracked profits consistently, falling close to zero relative to net income in 2024 and 2025 before recovering in 2026. Swings in investment spending or working capital can reduce cash-flow predictability and complicate funding and capital-allocation decisions.
Margin VariabilityThe sharp improvement in 2026 is encouraging, but the prior-year margin decline shows that profitability is not perfectly consistent. Periodic costs, product mix, or cyclical influences could therefore interrupt margin expansion and make medium-term earnings growth less linear.
Procedure-Volume ExposureMani’s recurring consumable sales benefit from repeated clinical use, but revenue remains tied to the volume of dental and surgical procedures. Changes in healthcare activity can therefore affect demand across both key product categories, limiting the company’s ability to grow independently of end-market utilization.
7730 FAQ
What was Mani, Inc.’s price range in the past 12 months?
Mani, Inc. lowest stock price was ¥1345.00 and its highest was ¥1955.00 in the past 12 months.
What is Mani, Inc.’s market cap?
Mani, Inc.’s market cap is ¥151.13B.
When is Mani, Inc.’s upcoming earnings report date?
Mani, Inc.’s upcoming earnings report date is Jan 13, 2027 which is in 83 days.
How were Mani, Inc.’s earnings last quarter?
Mani, Inc. released its earnings results on Oct 15, 2026. The company reported ¥16.19 earnings per share for the quarter, beating the consensus estimate of ¥14.193 by ¥1.997.
Is Mani, Inc. overvalued?
According to Wall Street analysts Mani, Inc.’s price is currently Overvalued.
Does Mani, Inc. pay dividends?
Mani, Inc. pays a Semiannually dividend of ¥18 which represents an annual dividend yield of 2.71%. See more information on Mani, Inc. dividends here
What is Mani, Inc.’s EPS estimate?
Mani, Inc.’s EPS estimate is 18.17.
How many shares outstanding does Mani, Inc. have?
Mani, Inc. has 107,003,280 shares outstanding.
What happened to Mani, Inc.’s price movement after its last earnings report?
Mani, Inc. reported an EPS of ¥16.19 in its last earnings report, beating expectations of ¥14.193. Following the earnings report the stock price went up 0.199%.
Which hedge fund is a major shareholder of Mani, Inc.?
Currently, no hedge funds are holding shares in JP:7730
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mani, Inc.
Mani, Inc. engages in the manufacture and supply of surgical and dental instruments in Japan, Asia, Europe, North America, and internationally. The company operates through three segments: Surgical Products, Eyeless Needle Products, and Dental Products. The company offers surgical instruments, such as maniplers, vessel knives, ENT knives, and stainless wire needles; and ophthalmic instruments, including ophthalmic sutures and knives, and trocar kits for vitrectomy. It also provides surgical eyeless, eyed, taper point, cutting, ophthalmic needles; and dental instruments, such as endodontic instruments, endodontic rotary instruments, root canal obturation, diamond and carbide burs, finishing and polishing instruments, sutures and surgical needles, endodontic micro-accessories, and endodontic accessories. Mani, Inc. was founded in 1956 and is headquartered in Utsunomiya, Japan.